MedTrace Logo

Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation

NCT02868424 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-06-16

No results posted yet for this study

Summary

Early Phase I Study of the Safety and Preliminary Efficacy of Human Fetal Retinal Pigment Epithelial(fRPE) Cells Subretinal Transplantation in Age-Related Macular Degeneration(AMD) Patients

Conditions

  • Age Related Macular Degeneration
  • Macular Degeneration
  • AMD

Interventions

DRUG

fRPE cells

fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Qinghuai Liu, M.D. · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-13
Primary Completion
2018-08-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02868424 on ClinicalTrials.gov